Samsung Biologics (Korea) Performance
| 207940 Stock | 939,000 19,000 1.98% |
The entity has a beta of 0.016, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Samsung Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Samsung Biologics is expected to be smaller as well. At this point, Samsung Biologics has a negative expected return of -0.0902%. Please make sure to validate Samsung Biologics' coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Samsung Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Samsung Biologics Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Samsung Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 28.9 B | |
| Total Cashflows From Investing Activities | -933.5 B |
Samsung |
Samsung Biologics Relative Risk vs. Return Landscape
If you would invest 100,000,000 in Samsung Biologics Co on September 23, 2024 and sell it today you would lose (6,100,000) from holding Samsung Biologics Co or give up 6.1% of portfolio value over 90 days. Samsung Biologics Co is generating negative expected returns and assumes 1.3998% volatility on return distribution over the 90 days horizon. Simply put, 12% of stocks are less volatile than Samsung, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Samsung Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Samsung Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Samsung Biologics Co, and traders can use it to determine the average amount a Samsung Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0645
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 207940 |
Estimated Market Risk
| 1.4 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Samsung Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Samsung Biologics by adding Samsung Biologics to a well-diversified portfolio.
Samsung Biologics Fundamentals Growth
Samsung Stock prices reflect investors' perceptions of the future prospects and financial health of Samsung Biologics, and Samsung Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Samsung Stock performance.
| Return On Equity | 0.0751 | |||
| Return On Asset | 0.0422 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 58.92 T | |||
| Shares Outstanding | 71.17 M | |||
| Price To Book | 6.92 X | |||
| Price To Sales | 23.45 X | |||
| Revenue | 1.57 T | |||
| EBITDA | 737.78 B | |||
| Total Debt | 1.11 T | |||
| Cash Flow From Operations | 454.6 B | |||
| Earnings Per Share | 2,418 X | |||
| Total Asset | 7.97 T | |||
About Samsung Biologics Performance
By analyzing Samsung Biologics' fundamental ratios, stakeholders can gain valuable insights into Samsung Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Samsung Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Samsung Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Samsung Biologics performance evaluation
Checking the ongoing alerts about Samsung Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Samsung Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Samsung Biologics generated a negative expected return over the last 90 days | |
| About 75.0% of the company shares are owned by insiders or employees |
- Analyzing Samsung Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Samsung Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Samsung Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Samsung Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Samsung Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Samsung Biologics' stock. These opinions can provide insight into Samsung Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Samsung Stock analysis
When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Correlations Find global opportunities by holding instruments from different markets |